CollPlant Biotechnologies
CLGN
21 hedge funds and large institutions have $819K invested in CollPlant Biotechnologies in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
24% more funds holding
Funds holding: 17 → 21 (+4)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.19% less ownership
Funds ownership: 10.79% → 10.61% (-0.19%)
58% less capital invested
Capital invested by funds: $1.93M → $819K (-$1.11M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$64.6K |
| 2 |
Pathstone Holdings
Englewood,
New Jersey
|
+$40.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$32.5K |
| 4 |
LWMI
Legacy Wealth Management (Idaho)
Boise,
Idaho
|
+$19.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$11.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Pinnacle Associates
New York
|
-$7.03K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$3.53K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3.5K |
| 4 |
PA
Parallel Advisors
San Francisco,
California
|
-$3.21K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.72K |
CLGN Hedge Fund Activity: Q1 2026 in Review
21 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q1 2026, worth a combined $819K — down 58% from $1.93M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CLGN positions and 1 closed out — a net gain of 4 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $64.6K. The largest seller was Pinnacle Associates, cutting an estimated $7.03K.
- 21 institutional investors held CollPlant Biotechnologies (CLGN) as of Q1 2026, up from 17 in Q4 2025.
- Funds reported $819K of CollPlant Biotechnologies stock for Q1 2026, down 58% quarter-over-quarter.
- 5 funds opened new CollPlant Biotechnologies positions in Q1 2026 and 1 closed out, a net change of +4 holders.
- The largest CollPlant Biotechnologies buyer in Q1 2026 was Armistice Capital, an estimated $64.6K added.
- The largest CollPlant Biotechnologies seller in Q1 2026 was Pinnacle Associates, an estimated $7.03K sold.
Based on aggregated 13F filings for Q1 2026.